Background: Sirolimus-eluting stents have recently been shown to reduce the risk of
restenosis among patients who undergo percutaneous coronary intervention (PCI). Given …

We evaluated the clinical effect of selective use of sirolimus-eluting stents (SESs) in real-
world, high-risk patients. A total of 4,237 consecutive patients who underwent percutaneous …

Background The cost effectiveness of drug-eluting stents in Canada is debated and
deserves further evaluation in high-risk patients. Methods We performed an economic …

Background The need for repeated treatment of restenosis of a treated vessel remains the
main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) …

ContextPlacement of sirolimus-eluting stents or paclitaxel-eluting stents has emerged as the
predominant percutaneous treatment strategy in patients with coronary artery disease …

The Registry Experience at the Washington Hospital Center with Drug-Eluting Stents
(REWARDS) study includes unselected patients with coronary artery disease treated with …

Background The long-term effects of treatment with sirolimus-eluting stents, as compared
with bare-metal stents, have not been established. Methods We performed an analysis of …

Background—The expanding indications for sirolimus-eluting stents (SES) include
increasingly complex coronary lesions and populations with clinical profiles markedly …

We investigated the clinical and economic impact of sirolimus-eluting coronary stents (SES)
at a nationwide level as to advice about the feasible reimbursement policy for the Italian …

Objectives: To compare the cost-effectiveness ratios of sirolimus-eluting stents (SES) with
bare-metal stents (BMS) under two perspectives: the “supplementary medical system”(health …